Therapeutic use of stem cells obtained from the cord umbilical in patients with diabetes mellitus type I

Daniela Villada Escobar and Karina Bustamante Galarza

South Health and Policy, 2024, vol. 3, 119-119

Abstract: Current medicine with a boom in stem cell therapies has great enthusiasm and hope to advance in the cure of some diseases that for many years have affected a large part of the world's population and that as the years go by, the incidence, relapses increase. of the disease, crisis, hospitalizations, comorbidities, complications that can not only affect the patient's health more, but also increase costs for hospitals and the state, in the midst of saving the lives of these patients; For years, the pharmaceutical industry has also produced different medications in search of a less invasive and more specific treatment for each patient, also increasing the cost of maintaining this disease; said disease diabetes mellitus (DM). Diabetes mellitus is a metabolic disease characterized by hyperglycemia and β-cell dysfunction. In this research we have the objective of focusing the therapeutics and efficacy on stem cells derived from the umbilical cord. that specifically provide several advantages and unique characteristics for said disease.

Date: 2024
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:dbk:southh:2024v3a50

DOI: 10.56294/shp2024119

Access Statistics for this article

More articles in South Health and Policy from AG Editor (Argentina)
Bibliographic data for series maintained by Javier Gonzalez-Argote ().